[CITATION][C] the Palivizumab Outcomes Study Group: Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season
M Sorrentino, T Powers�- Pediatr Infect Dis J, 2000
Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season
…, Palivizumab Outcomes Study Group�- …�infectious disease�…, 2000 - journals.lww.com
Background. Respiratory syncytial virus (RSV) remains a significant cause of morbidity,
especially in premature infants and immunocompromised children, resulting in
approximately 100 000 hospitalizations annually. A study was performed to evaluate the
outcomes of those given palivizumab (Synagis; MedImmune, Inc., Gaithersburg, MD) during
the 1998 to 1999 RSV season, its first season in general use. Methods. A retrospective chart
review of 1839 patients from 9 United States sites was conducted, representing all patients�…
especially in premature infants and immunocompromised children, resulting in
approximately 100 000 hospitalizations annually. A study was performed to evaluate the
outcomes of those given palivizumab (Synagis; MedImmune, Inc., Gaithersburg, MD) during
the 1998 to 1999 RSV season, its first season in general use. Methods. A retrospective chart
review of 1839 patients from 9 United States sites was conducted, representing all patients�…
Showing the best results for this search. See all results